Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 13, 2006

Vion Inks Manufacturing Deal for Anticancer Agent

  • Ben Venue Laboratories will manufacture Vion Pharmaceuticals’ Cloretazine, its lead anticancer agent, under a manufacturing agreement. 

    Cloretazine, an alkylating agent, is being evaluated in a Phase III trial in combination with cytarabine in relapsed acute myelogenous leukemia (AML) and a Phase II trial in elderly patients with previously untreated de novo poor-risk AML.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »